
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is positioned for potential upside driven by faster-than-expected growth in the spine market, increased sales in its Enabling Technologies segment, and improved profit margins. The company is currently trading below historical valuation levels, with substantial double-digit free cash flow growth and an 8% free cash flow yield, suggesting appealing investment opportunities. Despite a slight miss in 2Q25 base business results, there remains optimism regarding future profits, indicating a favorable outlook for sustained revenue growth.
Bears say
The financial outlook for Globus Medical Inc is negatively impacted by several key factors, including slower-than-expected growth in the spine market and potential revenue dis-synergies resulting from the acquisition of NuVasive. Additionally, the company's enabling technologies segment has experienced weaker growth, contributing to concerns about overall revenue expansion, which is projected to decelerate to low-single digits. Furthermore, anticipated challenges related to new product launches, competitive dynamics in the spine market, and possible declines in operating margins all pose risks to the firm’s financial performance.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares